Coronavirus Update: US Adds To Antibody Push With $486m AstraZeneca Deal
Plus: Bharat To Start Phase III Vaccine Trials Shortly
Executive Summary
After a week of monoclonal antibody therapies hitting the headlines - including a personal endorsement from President Trump - the US government bulks up its potential supplies. AZ's long-acting monoclonal antibody product enters large-scale trials for both a treatment and prophylaxis of COVID-19.
You may also be interested in...
Coronavirus Update: Praised By Trump, Regeneron Files Antibody Cocktail For Emergency Use Authorization
Trump's praise of the therapy and talk of a 'cure' for COVID-19 has raised concerns about misinformation and pressure on the US FDA once again.
Can Avigan Bite Into Buzzing Indian Favipiravir Market?
Fujifilm Toyama’s favipiravir may be relatively late on the Indian market,but local partner Dr Reddy’s believes that the large amount of safety data and superior shelf life of the product will hold it in good stead amid heightened competition. Local manufacturing could also help Dr Reddy’s pare the price differential with other versions.
Coronavirus Update: Favipiravir Scores In Phase III Trial
Glenmark's Phase III trial of the antiviral points to efficacy in mild-to-moderate COVID-19, but many physicians in India remain skeptical.
Need a specific report? 1000+ reports available
Buy Reports